These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 1701526)

  • 61. Racial differences in maternal serum human chorionic gonadotropin and unconjugated oestriol levels.
    Kulch P; Keener S; Matsumoto M; Crandall BF
    Prenat Diagn; 1993 Mar; 13(3):191-5. PubMed ID: 7685088
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Down syndrome and low maternal serum alpha fetoprotein.
    Jacobs S; Giles W
    Aust N Z J Obstet Gynaecol; 1990 Nov; 30(4):335-40. PubMed ID: 1707270
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy of screening for fetal Down syndrome in the United States from 1974 to 1997.
    Egan JF; Benn P; Borgida AF; Rodis JF; Campbell WA; Vintzileos AM
    Obstet Gynecol; 2000 Dec; 96(6):979-85. PubMed ID: 11084189
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Role of prenatal ultrasonography in women with positive screen for Down syndrome on the basis of maternal serum markers.
    Nyberg DA; Luthy DA; Cheng EY; Sheley RC; Resta RG; Williams MA
    Am J Obstet Gynecol; 1995 Oct; 173(4):1030-5. PubMed ID: 7485289
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Association of undetectable unconjugated estriol on multiple marker screening with steroid sulfatase deficiency.
    Jari SD; Fraer LM; Hogge WA
    Fetal Diagn Ther; 2004; 19(1):43-8. PubMed ID: 14646417
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Fetal nucleated red blood cell counts in peripheral blood of mothers bearing Down syndrome fetus.
    Parano E; Falcidia E; Grillo A; Takabayashi H; Trifiletti RR; Pavone P
    Neuropediatrics; 2001 Jun; 32(3):147-9. PubMed ID: 11521211
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The effect of fetal gender on the false-positive rate of Down syndrome by maternal serum screening.
    Mueller VM; Huang T; Summers AM; Winsor SH
    Prenat Diagn; 2005 Dec; 25(13):1258-61. PubMed ID: 16353275
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Maternal serum unconjugated estriol levels are lower in the presence of fetal Down syndrome.
    Haddow JE; Palomaki GE; Knight GJ; Canick JA; Wald NJ; Cuckle HS
    Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1372-4. PubMed ID: 1699418
    [No Abstract]   [Full Text] [Related]  

  • 69. Second trimester maternal serum alpha-fetoprotein (MSAFP) as predictor of fetal hemoglobin Bart's disease.
    Tongprasert F; Srisupundit K; Luewan S; Tongsong T
    Prenat Diagn; 2014 Dec; 34(13):1277-82. PubMed ID: 25046597
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A novel method for the detection of Down syndrome with the use of four serum markers.
    Azuma M; Yamamoto R; Wakui Y; Minobe S; Satomura S; Fujimoto S
    Am J Obstet Gynecol; 2002 Jul; 187(1):197-201. PubMed ID: 12114910
    [TBL] [Abstract][Full Text] [Related]  

  • 71. First-trimester alpha-fetoprotein screening for Down syndrome.
    Fuhrmann W; Altland K; Jovanovic V; Holzgreve W; Miny P; Wenger D; Rauskolb R
    Prenat Diagn; 1993 Mar; 13(3):215-8. PubMed ID: 7685089
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Screening for fetal Down syndrome with maternal serum hCG and oestriol: a prospective study.
    Herrou M; Leporrier N; Leymarie P
    Prenat Diagn; 1992 Nov; 12(11):887-92. PubMed ID: 1494541
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A technical and clinical evaluation of the new ThermoFisher BRAHMS unconjugated estriol and inhibin-A assays and their use in second trimester Down syndrome screening.
    Sahota DS; Tsang FHK; Gu JS; Fung WKV; Mok KY; Wong CL
    Scand J Clin Lab Invest; 2021 Sep; 81(5):371-378. PubMed ID: 34060966
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Autism Spectrum Disorder Risk in Relation to Maternal Mid-Pregnancy Serum Hormone and Protein Markers from Prenatal Screening in California.
    Windham GC; Lyall K; Anderson M; Kharrazi M
    J Autism Dev Disord; 2016 Feb; 46(2):478-88. PubMed ID: 26370672
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Maternal serum screening for fetal trisomy 18: a comparison of fixed cutoff and patient-specific risk protocols.
    Benn PA; Leo MV; Rodis JF; Beazoglou T; Collins R; Horne D
    Obstet Gynecol; 1999 May; 93(5 Pt 1):707-11. PubMed ID: 10912972
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effect of normal MSAFP screening on maternal age for genetic amniocentesis.
    Ganiats TG; Berry CC; Fullerton JT
    J Clin Epidemiol; 1990; 43(11):1143-8. PubMed ID: 1700812
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Maternal serum markers in screening for Down syndrome.
    Nørgaard-Pedersen B; Larsen SO; Arends J; Svenstrup B; Tabor A
    Clin Genet; 1990 Jan; 37(1):35-43. PubMed ID: 1689225
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Non-radioactive assay of AFP, hCG, and uE3 from dried blood specimens: a low-cost alternative for maternal screening for trisomy 21.
    Verloes A; Schoos R; Koulischer L
    Prenat Diagn; 1992 Dec; 12(12):1073-4. PubMed ID: 1283787
    [No Abstract]   [Full Text] [Related]  

  • 79. All MoMs are not equal: some statistical properties associated with reporting results in the form of multiples of the median.
    Bishop JC; Dunstan FD; Nix BJ; Reynolds TM; Swift A
    Am J Hum Genet; 1993 Feb; 52(2):425-30. PubMed ID: 7679245
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Incremental cost-effectiveness of incorporating oestriol evaluation in Down syndrome screening programmes.
    Ganiats TG; Halverson AL; Bogart MH
    Prenat Diagn; 1994 Jul; 14(7):527-35. PubMed ID: 7526362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.